For the Inventor, By the Inventor

Enter assignee name

Hwaseong-si, South Korea

Hanmi Pharm. Co., Ltd.

USPTO Granted Patents = 146

CIPO Patents = 90

EPO Patents = 67

Forward Citations = 469

where 'Filed Patents' based on already Granted Patents

where 'Inventors Filed' based on already Granted Patents

435 inventors (with patents filed for the assignee):

Se Chang Kwon (43 out of 89 patents)

Sung Youb Jung (36 out of 62 patents)

In Young Choi (20 out of 31 patents)

4. Kwee Hyun Suh (19 out of 25 patents)

5. Jong Soo Woo (18 out of 21 patents)

6. Gwan-Sun Lee (18 out of 23 patents)

7. Sung Min Bae (16 out of 30 patents)

8. Young Gil Ahn (16 out of 23 patents)

9. Dae Jin Kim (16 out of 33 patents)

10. Jae Hyun Park (15 out of 127 patents)

11. Young Jin Park (14 out of 88 patents)

12. Yong Il Kim (14 out of 75 patents)

13. In Hwan Bae (13 out of 14 patents)

14. Gwan Sun Lee (13 out of 44 patents)

15. Hyung Kyu Lim (12 out of 13 patents)

146 patents: Sort by Forward Citations

1. 12479845 - Imidazopyridine derivative compounds and use of same (2025-11-25),

2. 12435328 - Therapeutic enzyme fusion protein having a novel structure and use thereof (2025-10-07),

3. 12433867 - Pharmaceutical composition comprising FLT3 inhibitor and hypomethylating agent for treating acute myeloid leukemia (2025-10-07),

4. 12415842 - Immunostimulating IL-2 analogs (2025-09-16),

5. 12390533 - Protein complex comprising non-peptidyl polymer-coupled fatty acid derivative compound as linker and preparation method therefor (2025-08-19),

6. 12350315 - Methods of treating neutorpenia using G-CSF protein complex (2025-07-08),

7. 12350265 - Pharmaceutical composition for treating acute myeloid leukemia, containing FLT3 inhibitor and chemotherapeutic agents (2025-07-08),

8. 12325698 - Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same (2025-06-10),

9. 12319695 - Sulfonamide derivative with fused pyrimidine skeleton, having epidermal growth factor receptor mutation inhibitory effect (2025-06-03),

10. 12318430 - Methods of treating neutorpenia using G-CSF protein complex (2025-06-03),

11. 12274750 - Lyophilized formulation of long-acting human growth hormone immunoglobulin conjugate (2025-04-14),

12. 12227510 - Crystal form of acid addition salt of furopyrimidine compound (2025-02-18),

13. 12139455 - Polyethylene glycol derivative and use thereof (2024-11-12),

14. 12090248 - Crosslinked hyaluronic acid, hyaluronic acid hydrogel, and method for producing crosslinked hyaluronic acid and hyaluronic acid hydrogel (2024-09-17),

15. 12018060 - Glucagon derivatives (2024-06-25),

HANMI PHARM. CO., LTD. is a leading global pharmaceutical company that specializes in the research, development, manufacturing, and distribution of innovative healthcare solutions. With a strong focus on improving the quality of life for patients, Hanmi Pharm strives to provide top-notch products in various therapeutic areas. Their extensive portfolio includes prescription medicines, over-the-counter drugs, and medical devices. Committed to meeting the highest standards, Hanmi Pharm invests heavily in research and development, creating groundbreaking treatments and fostering collaborations with renowned academic institutions and biopharmaceutical partners. Through their dedication to innovation and excellence, Hanmi Pharm aims to contribute significantly to the advancement of global healthcare.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 2 2025

146 Patents

#2 in Hwaseong-si

#148 in South Korea

#5,417 in the World

Hwaseong-si, South Korea

Hanmi Pharm. Co., Ltd.

Forward Citations = 469

435 inventors:

Se Chang Kwon (43 out of 89 patents)

Sung Youb Jung (36 out of 62 patents)

In Young Choi (20 out of 31 patents)

4. Kwee Hyun Suh (19 out of 25 patents)

5. Jong Soo Woo (18 out of 21 patents)

Please report any incorrect information to support@idiyas.com

Loading…